Disc Medicine, Inc. (IRON) earnings date
Mar 11, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 10% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-20
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 37 days, typically, give or take 10 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 5, 2026 | before open | 36 | 8-K |
| Q2 FY2026 | Thu, Jul 30, 2026 | before open | 30 | 8-K |
| Q1 FY2026 | Tue, May 5, 2026 | before open | 35 | 8-K |
| Q4 FY2025 | Thu, Feb 26, 2026 | before open | 57 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | before open | 37 | 8-K |
| Q2 FY2025 | Thu, Aug 7, 2025 | before open | 38 | 8-K |
| Q1 FY2025 | Wed, May 7, 2025 | before open | 37 | 8-K |
| Q4 FY2024 | Thu, Feb 27, 2025 | before open | 58 | 8-K |
What they guided beta
| Q3 FY2026 | "Progressing Phase 2 study of selcodebart in patients with inflammatory bowel disease (IBD) with initial data expected in 2027 DISC-3405: Anti-TMPRSS6 Antibody (Hepcidin Induction)" exhibit |
| Q3 FY2026 | "Together with such net proceeds, we believe that our cash, cash equivalents, and marketable securities will be sufficient to fund our current operating and capital expenditure plans and our debt service obligations into 2030." exhibit |
| Q2 FY2026 | "Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026" exhibit |
| Q2 FY2026 | "Completed enrollment for RESTORE-PV Phase 2 study of DISC-3405 in polycythemia vera (PV) with initial data expected in Q3 2026 and progressing Phase 1b study of DISC-3405 in sickle cell disease (SCD) with initial data expected in Q4 2026" exhibit |
| Q2 FY2026 | "Along with an expected end of Phase 2 FDA interaction on selcodebart in MF anemia in Q4, we will potentially be positioned to advance two more programs into pivotal-stage development in 2027.”" exhibit |
| Q2 FY2026 | "On track to report APOLLO topline results in Q4 2026 and expect to submit CRL response and receive an FDA decision by mid-2027 o APOLLO completed enrollment in March 2026 and enrolled ahead of schedule with a final N of 183 Selcodebart (DISC-0974): Anti-Hemojuvelin Antibody (Hepcidin Suppression)" exhibit |
| Q2 FY2026 | "Additional data from RALLY-MF anticipated in Q4 2026, with an end-of-Phase 2 meeting with the FDA expected to occur by year-end" exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/IRON
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/IRON
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/IRON/"><img src="https://veritasdata.dev/embed/IRON.svg" alt="IRON earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/IRON/)
Script
<script async src="https://veritasdata.dev/embed/IRON.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/IRON"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.